CX-516, an AMPA modulator from Cortex Pharmaceuticals, is in phase I/IIa clinical trials for the symptomatic treatment of deficits in memory and cognition in Alzheimer's disease (AD) and similar disorders [234221]. CX-516 and other members in the series are also being investigated for possible antidepressant and antipsychotic activity. Results from initial studies showed that CX-691 and CX-519, both members of the AMPAkine family, have antidepressant activities [298828]. In January 1999, Cortex licensed AMPAkine technology rights to Organon for schizophrenia and depression [311499]. Cortex entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Diseases and Stroke, National Institutes of Health, for the initial clinical evaluation of CX-516 in AD patients [225777]. The results of a trial of CX-516 in combination with clozapine in schizophrenia patients were presented at the International Society for Schizophrenia Research in April 1999. CX-516 improved a number of aspects of cognitive function [321790].